Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Livogiva
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Pfenex received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Lead Product(s): CRM197
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Serum Institute of India Private Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 08, 2020
Pfenex is eligible to receive annual fees, milestone payments, and royalty based on net sales for all products developed by Serum Institute that use the CRM197 produced via Pfenex Expression Technology.